Literature DB >> 22822314

The new heparins.

Michael S Conners1, Samuel R Money.   

Abstract

Entities:  

Year:  2002        PMID： 22822314      PMCID： PMC3399228     

Source DB:  PubMed          Journal:  Ochsner J        ISSN： 1524-5012


× No keyword cloud information.
  25 in total

1.  Redesigning heparin.

Authors:  R D Rosenberg
Journal:  N Engl J Med       Date:  2001-03-01       Impact factor: 91.245

2.  The separation of active and inactive forms of heparin.

Authors:  L H Lam; J E Silbert; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-03-22       Impact factor: 3.575

3.  Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.

Authors:  M K Gould; A D Dembitzer; G D Sanders; A M Garber
Journal:  Ann Intern Med       Date:  1999-05-18       Impact factor: 25.391

4.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

Authors:  B I Eriksson; K A Bauer; M R Lassen; A G Turpie
Journal:  N Engl J Med       Date:  2001-11-01       Impact factor: 91.245

5.  A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.

Authors:  A G Turpie; A S Gallus; J A Hoek
Journal:  N Engl J Med       Date:  2001-03-01       Impact factor: 91.245

6.  Outpatient-based treatment protocols in the management of venous thromboembolic disease.

Authors:  A C Spyropoulos
Journal:  Am J Manag Care       Date:  2000-11       Impact factor: 2.229

7.  Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis.

Authors:  M D Gonze; K Salartash; W C Sternbergh; R A Baughman; A Leone-Bay; S R Money
Journal:  Circulation       Date:  2000-06-06       Impact factor: 29.690

8.  Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.

Authors:  H R Büller; M Gent; A S Gallus; J Ginsberg; M H Prins; R Baildon
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

9.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

10.  Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans.

Authors:  R A Baughman; S C Kapoor; R K Agarwal; J Kisicki; F Catella-Lawson; G A FitzGerald
Journal:  Circulation       Date:  1998-10-20       Impact factor: 29.690
View more
  2 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2002

2.  Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.

Authors:  Charlene V Chabata; James W Frederiksen; Lyra B Olson; Ibtehaj A Naqvi; Sharon E Hall; Ruwan Gunaratne; Bryan D Kraft; Loretta G Que; Lingye Chen; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2022-01-12       Impact factor: 4.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.